In mid-2011, despite the FDA’s initial rejection of Arena Pharmaceutical’s Lorcaserin, we predicted that in 2012 the FDA would approve Lorcaserin for the treatment of obesity. Now that the FDA has indeed approved Lorcaserin, to be marketed by Eisai Pharmaceuticals as Belviq, the outlook for obesity drugs — as well as devices — remains true to our forecast as laid out in Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019”.
The market for obesity drug and device treatment products is expected to experience a number of specific developments in the next 2-3 years, including other obesity drugs (Orexigen’s Contrave and Empatic, MetaCure’s Tantalus, and other drugs), obesity devices (BAROnova’s TransPyloric Shuttle, GI, Dynamics’ EndoBarrier, Silhouette’s nObese RF, and other devices), and changes in clinical practices, reimbursement and other drivers/limiters of obesity treatments.
The outlook for obesity treatments is therefore expected to follow the course forecasted by MedMarket Diligence, with the expected change in the landscape for obesity treatments across the multiple drug and device options as shown below:
Worldwide Market for Obesity Treatments, 2009 and 2019
Source: MedMarket Diligence, LLC; Report #S835.